The two-dose Pfizer and AstraZeneca COVID-19 vaccines are highly effective against the Delta variant which has become the dominant variant across the world, researchers at the Public Health England (PHE) have claimed.
According to a study published in the New England Journal of Medicine, two doses of Pfizer’s Coronavirus vaccines were 88% effective at preventing symptomatic infection from the Delta variant.
Similarly, two doses of AstraZeneca’s Coronavirus vaccines were 67% effective at preventing symptomatic infection from the Delta variant.
The study found that the first dose of Pfizer’s vaccine was 33% effective against symptomatic infection from the Delta variant while the first dose of AstraZeneca’s vaccine was 30% effective against symptomatic infection.
Previously, European Medicines Agency (EMA) had revealed that two-dose COVID-19 vaccines were vital in ensuring maximum protection against the Delta variant.
The Delta variant, first found in India late last year, has since become the dominant version of the virus worldwide and is behind a recent surge in infections reported in many countries including the UK and US. It has been detected in more than 90 countries around the world.